Pay in 4 interest-free payments of $6.88 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Mechanism map How Compounded Tirzepatide is positioned Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist that has shown up to 22.5% body weight reduction in the SURMOUNT trials
Their half-lives are 13 hours (LIRA) and 7 days (SEMA), allowing for daily and weekly subcutaneous administration, respectively, thanks to the structural modifications introduced.5,10 Effects on obesity and glycaemic control Both LIRA 3 mg and SEMA 2.4 mg have demonstrated a strong appetite-suppressing and satiety-promoting effect, as well as a delaying effect on gastric emptying.11,12 The SCALE programme highlighted the efficacy of LIRA 3 mg in reducing body weight and waist circumference13 and confirmed a reduction in HbA1c levels in individuals with diabetes, along with a decreased progression from prediabetes to diabetes after three years of treatment14 (Table 1)
:max_bytes(150000):strip_icc()/VWH-GettyImages-1807239973-944cddb21ce647c594217130457b8f00.jpg)
& Louw, R
Sure you can
When used appropriately, these claims can help communicate product benefits while remaining within regulatory guidelines
US$ 29.45
US$ 22.46
US$ 23.56
US$ 28.92
US$ 25.18
US$ 24.50
US$ 23.97
US$ 22.16
US$ 21.23
